AstraZeneca (LON:AZN) received a GBX 4,840 ($61.74) price objective from HSBC in a research note issued on Wednesday. The brokerage currently has a “sell” rating on the biopharmaceutical company’s stock. HSBC’s price objective suggests a potential downside of 18.46% from the stock’s previous close.
A number of other analysts have also weighed in on the stock. Berenberg Bank restated a “buy” rating and issued a GBX 6,200 ($79.09) target price on shares of AstraZeneca in a research report on Friday, June 8th. Deutsche Bank restated a “buy” rating and issued a GBX 6,000 ($76.54) target price (up previously from GBX 5,700 ($72.71)) on shares of AstraZeneca in a research report on Friday, July 13th. Goldman Sachs Group set a GBX 3,750 ($47.84) target price on shares of AstraZeneca and gave the company a “sell” rating in a research report on Wednesday, April 18th. Shore Capital restated a “hold” rating and issued a GBX 4,965 ($63.34) target price on shares of AstraZeneca in a research report on Thursday, April 19th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 5,500 ($70.16) target price on shares of AstraZeneca in a research report on Tuesday, April 24th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of GBX 5,605.09 ($71.50).
Shares of AstraZeneca stock opened at GBX 5,936 ($75.72) on Wednesday. AstraZeneca has a fifty-two week low of GBX 4,260 ($54.34) and a fifty-two week high of GBX 5,520 ($70.42).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: What does relative strength index mean?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.